CPIX (Cumberland Pharmaceuticals) Moat Score: 4/10 (As of Jun. 27, 2026)


CPIX Cumberland Pharmaceuticals Inc CPIX
32 GF Score
Price $6.75
GF Value $2.16
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Cumberland Pharmaceuticals Moat Score?

Cumberland Pharmaceuticals CPIX +12.50% 32 Moat Score is 4 as of Jun. 27, 2026. GuruFocus rates CPIX with a GF Score™ of 32/100 and a GF Value™ of $2.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Cumberland Pharmaceuticals ranks better than 90.71% on this metric.

Cumberland Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Cumberland Pharmaceuticals has Narrow Moat: Cumberland Pharmaceuticals has a modest moat due to its niche pharmaceutical products and some intellectual property. However, it faces competition from larger firms and lacks strong brand loyalty or significant cost advantages, limiting its market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cumberland Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

Cumberland Pharmaceuticals  (NAS:CPIX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cumberland Pharmaceuticals Moat Score Related Terms

CPIX vs CTOR, INCR, BGM: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cumberland Pharmaceuticals Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's Moat Score falls into.


CPIX
32GF Score
Cumberland Pharmaceuticals Inc CPIX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Cumberland Pharmaceuticals (CPIX) has a Moat Score of 4 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cumberland Pharmaceuticals ranks #96 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Cumberland Pharmaceuticals' Moat Score too high?
Cumberland Pharmaceuticals' current Moat Score is 4. Based on the distribution chart, Cumberland Pharmaceuticals ranks #96 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cumberland Pharmaceuticals has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' Moat Score compare to CTOR and INCR?
According to the Drug Manufacturers industry distribution chart, Cumberland Pharmaceuticals ranks #96 out of 1033 companies for Moat Score. This places Cumberland Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Cumberland Pharmaceuticals's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $6.75 — trading 212.5% above its estimated fair value. The current Moat Score is 4. Cumberland Pharmaceuticals' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current Moat Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?

Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued. The current stock price of $6.75 is trading 212.5% above its estimated GF Value™ of $2.16. GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CPIX:

  • Moat Score: 4
  • GF Value™: $2.16 vs. price of $6.75 (212.5% above fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cumberland Pharmaceuticals Business Description

Address 1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
32GF Score

Get the complete analysis for CPIX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.75
Price
$2.16
GF Value